Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

BIO Survey: 74% of Western Biopharmas Would Be Affected by WuXi AppTec Ban

publication date: May 9, 2024

BIO, the US-based biopharma trade association, reported that 74% of respondents to a survey have business with China CDMOs (mostly WuXi AppTec). As a result, US (and other non-China biopharma) companies would need up to eight years to find new CDMO partners without disrupting the drug development process if a law is passed that prohibits US biopharmas from doing business with WuXi AppTec. Three months ago, BIO forced WuXi AppTec out of its organization, based on undisclosed information that the company had stolen IP from its clientele. BIO decided to conduct a survey that measured how deeply WuXi is involved with western biopharmas, and the answer is clear: very deep indeed. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital